Cell Therapies
More potent than Autologous CAR-T
Nobel Laureate science, industry-grade scale-up, now accessible through Alloy
Originating from the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was developed through the T-CiRA program and advanced by Takeda. Now, Alloy offers democratized access to this powerful cell therapy engine, combining best-in-class science with a fully integrated, scalable drug development platform.
BOOST Protocol: The Breakthrough in Allogenic CAR-T
We have leveraged advanced boost protocols to enhance the potency, persistence, and precision of cell therapies. By engineering re-dosing strategies and supportive regimens into our platform, we enable modular, plug-and-play solutions that drive deeper responses, lower manufacturing costs, and improve safety profiles which are able to unlock more scalable and accessible treatments for patients.
Unprecedented potency
iCAR-T products demonstrate high potency via multiple mechanisms, including CAR- and TCR-mediated cytotoxicity and armoring strategies. The platform’s flexibility enables CAR engineering and armoring at the iT cell stage, accelerating development and allowing rapid testing of novel CARs or modifications—ultimately enhancing anti-tumor efficacy and supporting faster innovation in cell therapy design.
Plug and play product profile
The iPSC-derived iCAR-T platform is an off-the-shelf cell therapy solution using iPSCs engineered with γδTCR to produce uniform iPSC-γδT cells, reducing GvHD risk. Its modular design supports different TCRs and CARs, enabling broad therapeutic applications. A feeder-free differentiation process enhances scalability and consistency, making it a promising and versatile solution for clinical cell therapy development.
Low cost of manufacturing
The iPSC-T cell platform offers a cost-effective solution by using a feeder-free differentiation and robust expansion process, simplifying scale-up and reducing regulatory complexity. This optimized manufacturing approach, combined with deep expertise in iCAR-T biology, enables consistent production of high-quality, functional cryo-products at lower cost, supporting scalable and efficient cell therapy development.
Improved safety profile
Safety is central to the iPSC-T cell platform. Using γδTCR-transduced iPSC-derived T cells minimizes allo-GvHD risk, avoiding issues linked to αβTCRs. The platform produces highly functional, low-exhaustion iT cells, reducing adverse effects. Rigorous in vitro and in vivo characterization ensures the safety and efficacy of iCAR-T products for clinical use.
Collaborating to create the next generation of CAR-T therapies
Enhanced pharmaceutical applications
Best-in-class iPSC platform, developed through pharmaceutical industry-level collaboration to deliver a robust, reproducible, and high-quality solution.
Expanded Potency Capabilities
First allo CAR-T to consistently outperform autologous versions in potency, enabled by a robust Tcm phenotype and a log-order superiority in expansion capabilities.
Innovative Business Model
Unique business model that enables client programs (including other iPSC CAR-T) by emphasizing cash efficiency and end-to-end program management from discovery to clinical to life cycle management.
CAR-t Platform
Enabling the ideal substrate for CAR-T cell therapies
Alloy’s iCAR-T platform delivers a powerful combination of potency, persistence, innate immune function, and scalable manufacturing—advancing next-generation cell therapies with unmatched efficiency and therapeutic potential.
Superior potency
Consistently demonstrates enhanced expansion and cytotoxicity compared to autologous CAR-T therapies, as shown in preclinical animal models.
Central memory phenotype
Exhibits a phenotypic signature aligned with central memory T cells, with persistence beyond CAR-mediated expansion and cytolytic activity.
Innate immunity
CD8αβ-positive cells co-express γδTCR and natural cytotoxicity receptors, enabling innate-like killing to address antigen escape and tumor heterogeneity.
Efficient discovery and development
Breakthroughs in process control enable the creation of iPSC-derived T cell stocks and banks, streamlining discovery and development workflows.
Scalable manufacturing
Fully scaled for Phase 1–2 trials with consistent post-cryopreservation performance and a clear path to significant cost of goods sold (COGS) reduction compared to current conventional manufacturing.
Hypoimmune technology
Proprietary immune-editing reduces rejection risk, enhances iPSC-derived T cell engraftment, and enables off-the-shelf therapies for broad patient populations independent of HLA matching.
Fully Integrated iCAR-T workflow enabling efficient workflow from discovery and development to the clinic
In CAR-T cell therapies, every client has a unique innovation that enables potential breakthrough. Alloy leverages its end-to end integrated discovery and development platform to enable clients to accelerate to clinical entry with quality and capital efficiency.
CAR optimization
Alloy antibody discovery platforms and services enable superior binders with proprietary high efficiency CAR (binder/hinge) optimization
In-vitro and in-vivo pharmacology
Full service iCAR-T discovery to augment client capabilities with armoring, high efficiency pharmacology, and building client specific iT cell lines
Manufacturing enablement
Integrated service combining discovery to manufacturing with a preferred CDMO, or full tech transfer to CDMO of partners choice
Regulatory filing
Experience regulatory team consisting of experts in multiple cell therapy modalities, providing full support for iCAR-T Therapy and IND filing
Discuss partnering
Learn how to get started with our cell therapy platforms and or start a bespoke project together.
